Related Experiment Video
Updated: Aug 19, 2026

Use of a Hanging-weight System for Isolated Renal Artery Occlusion
Published on: July 19, 2011
Anticoagulation during continuous renal replacement therapy
1Department of Medicine, University of California, San Diego.
Insights
Anticoagulation is crucial for continuous renal replacement therapy (CRRT) filter function. Selecting the right anticoagulant considers patient factors, access, and membrane type to prevent complications.
Area of Science:
- Nephrology
- Critical Care Medicine
Background:
- Anticoagulation is vital for the function and longevity of filters used in continuous venovenous hemofiltration (CAVH) or CAVHD and is a critical challenge in continuous renal replacement therapy (CRRT).
- Multiple anticoagulation strategies are available, allowing for selection based on patient-specific characteristics, anticoagulant availability, and institutional expertise.
Purpose of the Study:
- To review and discuss the factors influencing the choice of anticoagulation in CRRT.
- To highlight the importance of careful selection and monitoring of anticoagulation to prevent complications.
Main Methods:
- Review of current anticoagulation options and influencing factors in CRRT.
- Discussion of patient-specific considerations for anticoagulant selection.
Main Results:
- Anticoagulant choice depends on access site, pump use, membrane characteristics, ultrafiltration enhancements (e.g., predilution), and patient's clinical status and coagulation profile.
- Continuous anticoagulation in CRRT requires longer duration and thus more meticulous management than in intermittent hemodialysis.
Conclusions:
- Careful selection and vigilant monitoring of anticoagulation are essential for successful CRRT and prevention of filter-related complications.
- Tailoring anticoagulation strategies to individual patient needs and treatment parameters optimizes filter performance and patient safety.
Abstract:
Proper anticoagulation is an important factor in the function and life of the filter in CAVH or CAVHD and is the Achilles heel for CRRT. Several options now exist for anticoagulation and can be selected based on individual patient characteristics, availability of various anticoagulants, and local expertise. The choice of anticoagulant should be based on multiple factors, including A) the access site and whether an external pump is being used; B) the nature and geometry of the membrane; C) whether enhancements for ultrafiltration, such as predilution, are used; and D) the clinical status of the patient and preexisting coagulation abnormalities. Since anticoagulation in continuous therapy lasts longer than in intermittent hemodialysis, careful selection and monitoring are essential to prevent complications.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Venous Thrombosis III: Interprofessional Care
Continuous Renal Replacement Therapy
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care

